Uniqure NV
QURE13.497USD
-0.198-1.45%
交易中 （美东）报价延迟15分钟
740.52M总市值
亏损市盈率 TTM
关于 Uniqure NV 公司
Uniqure NV 是一家总部位于荷兰的基因治疗公司。该公司致力于开发一次性给药的治疗方法，为患有遗传性疾病和其他毁灭性疾病的患者提供潜在的治愈效果。该公司通过内部和合作伙伴开发了一系列基因疗法。该公司在自己的工厂中生产基于腺相关病毒（或 AAV）的基因疗法，采用专有的、商业规模的、符合现行良好生产规范的制造工艺。AMT-061 是该公司针对血友病 B 患者的主要候选产品，目前正在进行关键研究的给药阶段。AMT-130 是针对亨廷顿氏病患者的候选产品，目前正处于 I/II 期临床研究阶段。
公司简介
公司代码QURE
公司名称Uniqure NV
上市日期Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
员工数量209
证券类型Ordinary Share
年结日Feb 05
公司地址Paasheuvelweg 25a
城市AMSTERDAM
上市交易所NASDAQ Global Select Consolidated
国家Netherlands
邮编1105 BP
电话31202406000
网址https://www.uniqure.com/
公司代码QURE
上市日期Feb 05, 2014
CEOMr. Matthew (Matt) Kapusta, CPA
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
Ms. Rachelle Suzanne Jacques
Ms. Rachelle Suzanne Jacques
Non-Executive Independent Director
Non-Executive Independent Director
20.27K
+40.66%
Dr. Jeannette Potts, J.D., Ph.D.
Dr. Jeannette Potts, J.D., Ph.D.
Chief Legal and Compliance Officer and Corporate Secretary
Chief Legal and Compliance Officer and Corporate Secretary
15.67K
-22.96%
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. David Meek
Mr. David Meek
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Christian Klemt, CPA
Mr. Christian Klemt, CPA
Chief Financial Officer
Chief Financial Officer
99.26K
+57.56%
Dr. Robert Gut, M.D., Ph.D.
Dr. Robert Gut, M.D., Ph.D.
Non-Executive Director
Non-Executive Director
47.66K
+10.77%
Walid Abi-Saab
Walid Abi-Saab
Chief Medical Officer
Chief Medical Officer
34.63K
-4.06%
Mr. Madhavan (Madhu) Balachandran
Mr. Madhavan (Madhu) Balachandran
Non-Executive Independent Director
Non-Executive Independent Director
29.62K
+24.66%
Dr. Jeremy P. Springhorn, Ph.D.
Dr. Jeremy P. Springhorn, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
29.61K
+24.66%
Dr. Leonard E. Post, Ph.D.
Dr. Leonard E. Post, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.86K
+36.61%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
持股股东
持股股东
占比
Vestal Point Capital, LP
8.73%
RTW Investments L.P.
7.77%
EcoR1 Capital, LLC
7.27%
Nantahala Capital Management, LLC
5.02%
abrdn Inc.
5.01%
Other
66.18%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
47.15%
Hedge Fund
23.24%
Investment Advisor
15.35%
Corporation
4.36%
Research Firm
3.09%
Venture Capital
2.58%
Individual Investor
1.72%
Private Equity
0.84%
Bank and Trust
0.06%
Other
1.60%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
394
54.93M
100.44%
-2.00M
2025Q1
429
55.29M
101.00%
-4.83M
2024Q4
431
46.57M
86.23%
-10.92M
2024Q3
431
43.93M
89.29%
-10.96M
2024Q2
435
37.07M
76.08%
-15.19M
2024Q1
449
38.56M
80.27%
-17.69M
2023Q4
454
43.54M
90.77%
-8.61M
2023Q3
462
41.52M
86.64%
-16.34M
2023Q2
452
41.43M
87.10%
-18.53M
2023Q1
454
47.06M
99.04%
-12.29M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Vestal Point Capital, LP
4.79M
8.75%
+1.77M
+58.43%
Mar 31, 2025
RTW Investments L.P.
4.27M
7.79%
+3.36M
+372.04%
Mar 31, 2025
EcoR1 Capital, LLC
3.99M
7.29%
+588.97K
+17.32%
Mar 31, 2025
Nantahala Capital Management, LLC
2.76M
5.03%
+302.60K
+12.33%
Mar 31, 2025
abrdn Inc.
2.22M
4.05%
+706.22K
+46.79%
Mar 31, 2025
Bristol Myers Squibb
2.39M
4.36%
--
--
Sep 30, 2024
Avoro Capital Advisors LLC
2.17M
3.97%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
1.99M
3.63%
--
--
Mar 31, 2025
Two Sigma Investments, LP
1.58M
2.9%
-50.79K
-3.10%
Mar 31, 2025
683 Capital Management LLC
1.55M
2.83%
+25.00K
+1.64%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Invesco Dorsey Wright Healthcare Momentum ETF
1.53%
WisdomTree BioRevolution Fund
1.09%
Global X Genomics & Biotechnology ETF
0.88%
Virtus LifeSci Biotech Clinical Trials ETF
0.78%
Main Thematic Innovation ETF
0.46%
Invesco NASDAQ Future Gen 200 ETF
0.43%
SPDR S&P Biotech ETF
0.24%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Invesco Nasdaq Biotechnology ETF
0.09%
ProShares Ultra Nasdaq Biotechnology
0.09%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
占比1.53%
WisdomTree BioRevolution Fund
占比1.09%
Global X Genomics & Biotechnology ETF
占比0.88%
Virtus LifeSci Biotech Clinical Trials ETF
占比0.78%
Main Thematic Innovation ETF
占比0.46%
Invesco NASDAQ Future Gen 200 ETF
占比0.43%
SPDR S&P Biotech ETF
占比0.24%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.14%
Invesco Nasdaq Biotechnology ETF
占比0.09%
ProShares Ultra Nasdaq Biotechnology
占比0.09%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
